Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by de Ziegler, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Ziegler, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 18, No. 8, 1598-1602, August 2003
© 2003 European Society of Human Reproduction and Embryology

Commentary

Associate editor's commentary: The dawning of the non-cancer uses of aromatase inhibitors in gynaecology

Dominique de Ziegler1

Department of Obstetrics and Gynecology, Hopital de Nyon, 1260 Nyon, Switzerland

1 To whom correspondence should be addressed. e-mail: ddeziegler@bluewin.ch

The first 150 words of the full text of this article appear below.


   New drugs in gynaecology
 
It is always a treat to witness the unearthing of new drugs in our field. The aromatase inhibitor, letrozole, approved in 1997 for treating advanced breast cancer (Cohen et al., 2002Go) falls in the category of new products for which numerous other possible applications exist. Designed for suppressing estradiol (E2) production, products such as letrozole could become useful either in the short-term for inducing or facilitating ovulation or in the longer-term for treatment of endometriosis and possibly, uterine fibroids. This situation resembles that which prevailed some 15 years ago with GnRH agonists. Approved for treating prostate cancer, GnRH agonists were soon tested and used in an array of other applications in gynaecology, including in controlled ovarian hyperstimulation (COH) (Droesch et al., 1989Go). We now know the multitude of uses for GnRH agonists, whereas those of aromatase inhibitors are unravelling before our eyes.

In the current issue . . . [Full Text of this Article]


   Induction of ovulation and COH
 

   Questions remaining about using aromatase inhibitors in COH
 
Timing of aromatase inhibitor treatments
Dosing letrozole
Risk of premature LH surge and need for GnRH antagonists
Quality of oocytes

   Other possible uses of aromatase inhibitors in gynaecology
 

   Approval of new drugs and the practice of medicine
 

   Acknowledgement
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
K. Lossl, A.N. Andersen, A. Loft, N.L.C. Freiesleben, S. Bangsboll, and C.Y. Andersen
Androgen priming using aromatase inhibitor and hCG during early-follicular-phase GnRH antagonist down-regulation in modified antagonist protocols
Hum. Reprod., October 1, 2006; 21(10): 2593 - 2600.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
R. Homburg
Clomiphene citrate--end of an era? a mini-review
Hum. Reprod., August 1, 2005; 20(8): 2043 - 2051.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J. Brosens, H. Verhoeven, R. Campo, L. Gianaroli, S. Gordts, J. Hazekamp, L. Hagglund, T. Mardesic, E. Varila, J. Zech, et al.
High endometrial aromatase P450 mRNA expression is associated with poor IVF outcome
Hum. Reprod., February 1, 2004; 19(2): 352 - 356.
[Abstract] [Full Text] [PDF]